Related Experiment Video
Updated: Jun 2, 2026
09:03
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Lymphangiogenesis and hemangiogenesis: potential targets for therapy
Marlys H Witte1, Michael T Dellinger, Donald M McDonald
1Department of Surgery, University of Arizona College of Medicine, Tucson, Arizona 85724-5200, USA. grace@surgery.arizona.edu
Journal of Surgical Oncology
|April 12, 2011
Summary
This review details the molecular basis of lymphatic system development, known as molecular lymphology. It covers lymphatic vasculature adaptations, cancer spread via lymphatics, and anti-lymphangiogenesis cancer therapies.
Area of Science:
- Vascular Biology
- Developmental Biology
- Cancer Biology
Background:
- Historical context of embryonic lymphatic system development.
- Evolution of understanding from early observations to molecular mechanisms.
- Comparison with blood vasculature development.
Purpose of the Study:
- To provide an updated review on lymphvasculogenesis and lymphangiogenesis.
- To highlight molecular mechanisms and structural adaptations of lymphatic vasculature.
- To discuss the role of lymphatics in cancer progression and therapy.
Main Methods:
- Literature review of historical and current research.
- Synthesis of data on molecular mechanisms.
- Analysis of lymphatic system's role in transport and cancer.
Main Results:
- Elucidation of molecular mechanisms driving lymphatic development.
- Understanding of structural adaptations for transport and trafficking.
- Identification of lymphogenous routes in cancer metastasis.
- Insights into preserving lymphatic pathways during surgery.
- Evaluation of anti-lymphangiogenesis strategies in cancer treatment.
Conclusions:
- Lymphatic system development shares similarities and differences with blood vasculature.
- The lymphatic system plays a critical role in cancer spread.
- Targeting lymphangiogenesis offers potential for cancer therapy.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...